214 related articles for article (PubMed ID: 15627788)
1. Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients.
Reichel H; Roth HJ; Schmidt-Gayk H
Nephron Clin Pract; 2004; 98(4):c112-8. PubMed ID: 15627788
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients.
Okuno S; Inaba M; Kitatani K; Ishimura E; Yamakawa T; Nishizawa Y
Osteoporos Int; 2005 May; 16(5):501-9. PubMed ID: 15309383
[TBL] [Abstract][Full Text] [Related]
3. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
4. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
5. Markers of bone resorption--measurement in serum, plasma or urine?
Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
[TBL] [Abstract][Full Text] [Related]
6. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
Al-Awadhi A; Olusi S; Al-Zaid N; Prabha K
J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038
[TBL] [Abstract][Full Text] [Related]
7. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients.
Ureña P; Ferreira A; Kung VT; Morieux C; Simon P; Ang KS; Souberbielle JC; Segre GV; Drüeke TB; De Vernejoul MC
J Bone Miner Res; 1995 Jun; 10(6):932-9. PubMed ID: 7572317
[TBL] [Abstract][Full Text] [Related]
8. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS
Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
[TBL] [Abstract][Full Text] [Related]
9. Effect of acute citrate load on markers of bone metabolism in healthy volunteers.
Chen Y; Bieglmayer C; Höcker P; Dettke M
Vox Sang; 2009 Nov; 97(4):324-9. PubMed ID: 19508702
[TBL] [Abstract][Full Text] [Related]
10. Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover.
Alvarez L; Torregrosa JV; Peris P; Monegal A; Bedini JL; Martinez De Osaba MJ; Filella X; Martin G; Ricos C; Oppenheimer F; Ballesta AM
J Bone Miner Metab; 2004; 22(3):254-9. PubMed ID: 15108068
[TBL] [Abstract][Full Text] [Related]
11. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
Ueda M; Inaba M; Okuno S; Maeno Y; Ishimura E; Yamakawa T; Nishizawa Y
Life Sci; 2005 Jul; 77(10):1130-9. PubMed ID: 15978265
[TBL] [Abstract][Full Text] [Related]
12. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
13. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of PTH (1-84) and PTH (7-84) in patients with predialysis chronic renal failure in relation to bone metabolism markers].
Tsuchida T; Ishimura E; Hirowatari K; Matsumoto N; Jono S; Miki T; Inaba M; Nishizawa Y
Clin Calcium; 2005 Sep; 15 Suppl 1():156-60; discussion 160. PubMed ID: 16272650
[TBL] [Abstract][Full Text] [Related]
15. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
Christgau S; Bitsch-Jensen O; Hanover Bjarnason N; Gamwell Henriksen E; Qvist P; Alexandersen P; Bang Henriksen D
Bone; 2000 May; 26(5):505-11. PubMed ID: 10773591
[TBL] [Abstract][Full Text] [Related]
16. Cross-sectional evaluation of bone metabolism in men.
Szulc P; Garnero P; Munoz F; Marchand F; Delmas PD
J Bone Miner Res; 2001 Sep; 16(9):1642-50. PubMed ID: 11547833
[TBL] [Abstract][Full Text] [Related]
17. Cross-linked C-terminal telopeptide of type I collagen in serum before and after treatment with alfacalcidol and calcium carbonate in early and moderate chronic renal failure.
Przedlacki J; Trebicka J; Bijak K; Matuszkiewicz-Rowińska J; Bogdańska-Straszyńska B; Małecka G; Ostrowski K
Nephron; 2002 Oct; 92(2):304-8. PubMed ID: 12218307
[TBL] [Abstract][Full Text] [Related]
18. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
19. Body mass index and disease duration are predictors of disturbed bone turnover in anorexia nervosa. A case-control study.
Weinbrenner T; Zittermann A; Gouni-Berthold I; Stehle P; Berthold HK
Eur J Clin Nutr; 2003 Oct; 57(10):1262-7. PubMed ID: 14506487
[TBL] [Abstract][Full Text] [Related]
20. [Bone biomarkers in haemodialysis patients: bone alkaline phosphatase or ß-Crosslaps?].
Jean G; Souberbielle JC; Granjon S; Lorriaux C; Hurot JM; Mayor B; Deleaval P; Chazot C
Nephrol Ther; 2013 Jun; 9(3):154-9. PubMed ID: 23545236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
